Navigation Links
Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
Date:8/31/2010

SAN DIEGO, Aug. 31 /PRNewswire/ -- Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients. During hemorrhagic shock, inadequate perfusion of critical organs can lead to insufficient oxygenation of tissues, which can be detected by an increase in lactate levels. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.

Study data show a statistically significant greater immediate and sustained decrease of lactic acid in patients treated with MP4OX compared to patients in the control group. The study also found that a greater proportion of patients treated with MP4OX were able to attain normal lactate levels as early as four hours post-treatment. Furthermore, data demonstrated a strong trend toward outcomes benefits through multiple measures, including reducing the average total number of days patients spent in hospital. In patients treated with MP4OX, the median hospital stay was half that of the control group. Serious adverse events were of equal rates and similar in nature between the MP4OX-treated and control groups.

"Trauma patients suffer organ dysfunction from shock and lack of oxygen supply to vital tissues.  Prolonged lactic acidosis, a marker of shock, correlates with a worse outcome and higher mortality rate. This study suggests that MP4OX has the ability to improve oxygen delivery to the body and subsequently reduce organ failure and other complications," said Karim Brohi, Professor of Trauma Sciences at Barts and the London School of Medicine & Dentistry and lead study investigator. "We are excited by the results from this study as they suggest that MP4OX has the potential to
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Series F Funding Round
3. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. Par Pharmaceutical Reports Second Quarter 2008 Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Pharmos Corporation Reports 2008 Second Quarter Results
9. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
10. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Not even geckos and spiders can sit upside down forever. ... have demonstrated this in an article just published in ... industrial benefit. , Geckos and spiders that seem to be ... have fascinated researchers worldwide for many years. We will soon ... same way as the gecko,s foot. But the fact is, ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
(Date:1/15/2014)... akin to assembling a club sandwich at the ... researchers have succeeded in crafting a uniform, multi-walled ... foam commonly used in upholstered furniture and other ... polyurethane foam was reduced 35 percent compared with ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood Center and ... blood drive. The drive takes place Saturday, Jan. 18 at ... - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
Breaking Biology Technology:Even geckos can lose their grip 2University of Illinois study advances limits for ultrafast nano-devices 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... of Convertible Preferred Stock -, DALLAS, Jan. ... announced today that it has executed agreements,for $2.7 ... into agreements,with institutional and accredited investors to purchase ... the Company,s Series A Convertible,Preferred Stock. This equity ...
... Healionics Corporation, a,provider of tissue regeneration and ... it has raised $1.7 million,in a Series A ... Carl Lombardi, former CEO of SpaceLabs Medical and ... & Rejuvenation Center., "We are pleased to ...
... in cash at year end; no equity financings expected ... disease programs to continue in,2008; latest data for all ... - Expansion of research and development investment ... lysosomal diseases in 2008, CRANBURY, N.J., Jan. 29 ...
Cached Biology Technology:Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3Healionics Corporation Completes Series A Financing 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... non-native mussels in the Great Lakes has caused ... two of the planet,s largest freshwater lakes, according ... The blitzkrieg advance of two closely related species ... of their life-supporting algae, resulting in a remarkable ...
... 2011 A natural hormone known to inhibit aging can ... researchers have demonstrated. Scientists led by Dr. Makoto Kuro-o, ... hormone Klotho suppressed both renal fibrosis a common complication ... The findings are available online in the Journal of ...
... warming may be the greatest challenge of the present generation. ... the average citizen often wonders what he or she can ... FROM GERMANY,S SUCCESS IN HARNESSING CLEAN ENERGY" (Prometheus Books, $19) ... in the making veteran science and technology journalist Bob ...
Cached Biology News:Invasive mussels causing massive ecological changes in Great Lakes 2Invasive mussels causing massive ecological changes in Great Lakes 3Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Switching to solar 2